1,405 results match your criteria Current Oncology [Journal]


Does the presence of emphysema increase the risk of radiation pneumonitis in lung cancer patients?

Curr Oncol 2018 Dec 1;25(6):e610-e614. Epub 2018 Dec 1.

Peter Brojde Lung Cancer Centre, Sir Mortimer B. Davis Jewish General Hospital, Montreal, QC.

Introduction: Radiotherapy (rt) plays an important role in the treatment of lung cancer. One of the most common comorbidities in patients with lung cancer is pulmonary emphysema. The literature offers conflicting data about whether emphysema increases the occurrence and severity of radiation pneumonitis (rp). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291283PMC
December 2018
3 Reads

Developing a model of a patient-group pathway to accessing cancer clinical trials in Canada.

Curr Oncol 2018 Dec 1;25(6):e597-e609. Epub 2018 Dec 1.

Colorectal Cancer Canada, Montreal, QC.

Background: Colorectal Cancer Canada, in partnership with a Scientific Advisory Committee, is developing a Canadian Patient Group Pathway to Accessing Cancer Clinical Trials ("Pathway"). A central element of the Pathway is presented here-namely, a set of recommendations and tools aimed at each stakeholder group.

Methods: A summary of the peer-reviewed and grey literature informed discussions at a meeting, held in June 2017, in which a cross-section of stakeholders reached consensus on the potential roles of patient groups in the cancer clinical trials process, barriers to accessing cancer clinical trials, best practice models for patient-group integration, and a process for developing the Pathway. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291290PMC
December 2018
1 Read

Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.

Curr Oncol 2018 Dec 1;25(6):e592-e596. Epub 2018 Dec 1.

Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC.

Primary effusion lymphoma (pel) is a rare human herpesvirus 8 (hhv8)-related large B cell lymphoma with plasmablastic, immunoblastic, or anaplastic features that often carries a poor prognosis. This lymphoma occurs mainly in patients with hiv infection, most often with Epstein-Barr virus (ebv) co-infection, and usually presents as body cavity effusions or, less commonly, as extracavitary lesions without effusion (ec-pel). Chemotherapeutic treatment options are limited and require concurrent antiretroviral therapy (art). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291272PMC
December 2018
3 Reads

Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.

Authors:
M Le May S Dent

Curr Oncol 2018 Dec 1;25(6):e585-e591. Epub 2018 Dec 1.

Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, ON.

Breast cancer is the most common cancer in women, with 15%-25% of those tumours overexpressing the human epidermal growth factor receptor 2 (her2), which is associated with more aggressive disease. On rare occasions, patients present with a paraneoplastic syndrome months to years before their cancer diagnosis. Paraneoplastic cerebellar degeneration (pcd) is associated with fewer than 1% of cancers and is strongly associated with breast and gynecologic malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291278PMC
December 2018
2 Reads

Use of targeted therapy in patients with metastatic renal cell carcinoma: clinical and economic impact in a Canadian real-life setting.

Curr Oncol 2018 Dec 1;25(6):e576-e584. Epub 2018 Dec 1.

McGill University Health Centre, Montreal, QC.

Introduction: Outside of randomized controlled clinical trials, the understanding of the effectiveness and costs associated with targeted therapies for metastatic renal cell carcinoma (mrcc) is limited in Canada. The purpose of the present study was to use real-world prospective data to assess the effectiveness and cost of targeted therapies for patients with mrcc.

Methods: The Canadian Kidney Cancer Information System, a pan-Canadian database, was used to identify prospectively collected data relating to patients with mrcc. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291289PMC
December 2018
2 Reads

Survival of patients with subglottic squamous cell carcinoma.

Curr Oncol 2018 Dec 1;25(6):e569-e575. Epub 2018 Dec 1.

Institute for Clinical Evaluative Sciences, Toronto, ON.

Objective: Subglottic squamous cell carcinoma is a rare subsite of laryngeal cancer that behaves more aggressively and portends a worse prognosis. Using a population-based cancer registry, our objective was to report overall survival (os) and laryngectomy-free survival (lfs) in patients diagnosed with subglottic squamous cell carcinoma, and to determine whether primary laryngectomy results in improved survival.

Methods: This retrospective population-based study considered patients with a new diagnosis of squamous cell carcinoma in the province of Ontario over a 15-year period (1995-2009). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3864DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291284PMC
December 2018
5 Reads

Contralateral prophylactic mastectomy in young women with breast cancer: a population-based analysis of predictive factors and clinical impact.

Curr Oncol 2018 Dec 1;25(6):e562-e568. Epub 2018 Dec 1.

Division of Surgical Oncology, University of Calgary, Calgary, AB.

Background And Objectives: Contralateral prophylactic mastectomy (cpm) has been increasingly common among women with unilateral invasive breast cancer (ibca) even though the data that support it are limited. Using a population-based cohort, the objectives of the present study were to describe factors predictive of cpm in young women (≤35 years) with ibca and to evaluate the impact of the procedure on mortality.

Methods: All women diagnosed during 1994-2003 and treated with cpm were identified from the Ontario Cancer Registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4169DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291287PMC
December 2018
1 Read

Patient-reported outcome measurement compared with professional judgment of cosmetic results after breast-conserving therapy.

Curr Oncol 2018 Dec 1;25(6):e553-e561. Epub 2018 Dec 1.

Department of Surgery, Máxima Medical Center, Veldhoven, Netherlands.

Background: In the present study, we set out to compare patient-reported outcomes with professional judgment about cosmesis after breast-conserving therapy (bct) and to evaluate which items (position of the nipple, color, scar, size, shape, and firmness) correlate best with subjective outcome.

Methods: Dutch patients treated with bct between 2008 and 2009 were analyzed. Exclusion criteria were prior amputation or bct of the contralateral breast, metastatic disease, local recurrence, or any prior cosmetic breast surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291275PMC
December 2018
1 Read

Appropriate treatment receipt after breast-conserving surgery.

Curr Oncol 2018 Dec 1;25(6):e545-e552. Epub 2018 Dec 1.

Schulich School of Medicine and Dentistry, Western University, London.

Background: Breast-conserving surgery (bcs) and radiation therapy (rt) are the standard of care for early breast cancer, although some women receive ipsilateral mastectomy or adjuvant tamoxifen, both of which can be appropriate alternatives to rt. Objectives of the present study were to determine the proportion of women who are treated appropriately after bcs and to identify factors associated with non-receipt of rt.

Methods: This retrospective cohort study used Ontario data linked at the Institute for Clinical and Evaluative Sciences to examine 33,718 patients who received bcs during 2004-2010. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291280PMC
December 2018
1 Read

Incidence of spinal disease and role of spinal radiotherapy in multiple myeloma.

Curr Oncol 2018 Dec 1;25(6):e539-e544. Epub 2018 Dec 1.

Department of Radiation Oncology, CancerCare Manitoba, Winnipeg, MB, U.S.A.

Background: Spinal disease (spd) in multiple myeloma (mm) can be a major source of morbidity in newly diagnosed patients and long-term survivors. We retrospectively assessed the incidence of spinal disease in patients newly diagnosed with myeloma, its effect on survival, and the possible effect of spinal radiation therapy (rt).

Methods: Patients diagnosed with mm between 2010 and 2014 were identified through the provincial cancer registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291270PMC
December 2018
5 Reads

Impact of high-fidelity e-learning on knowledge acquisition and satisfaction in radiation oncology trainees.

Curr Oncol 2018 Dec 1;25(6):e533-e538. Epub 2018 Dec 1.

Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, ON.

Background: e-Learning is an underutilized tool in education for the health professions, and radiation medicine, given its reliance on technology for clinical practice, is well-suited to training simulation in online environments. The purpose of the present study was to evaluate the knowledge impact and user interface satisfaction of high-(hf) compared with low-fidelity (lf) e-learning modules (e-modules) in radiation oncology training.

Methods: Two versions of an e-module on lung radiotherapy (lf and hf) were developed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4090DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291292PMC
December 2018
1 Read

Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients.

Curr Oncol 2018 Dec 1;25(6):e527-e532. Epub 2018 Dec 1.

Women's Health Reference Center, Hospital Perola Byington, Sao Paulo, Brazil.

Background: Fertility preservation is an important concern in breast cancer patients. In the present investigation, we set out to create a specific protocol of controlled ovarian stimulation (cos) for oocyte cryopreservation in breast cancer patients.

Methods: From November 2014 to December 2016, 109 patients were studied. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3889DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291279PMC
December 2018
2 Reads

Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response.

Curr Oncol 2018 Dec 1;25(6):e516-e526. Epub 2018 Dec 1.

Division of Medical Oncology, Department of Medicine, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON.

Background: Adrenergic receptor stimulation is involved in the development of hypertension (htn) and has been implicated in cancer progression and dissemination of metastases in various tumours, including colon cancer. Adrenergic antagonists such as beta-blockers (bbs) demonstrate inhibition of invasion and migration in colon cancer cell lines and have been associated with decreased mortality in colorectal cancer (crc). We examined the association of baseline htn and bb use with overall (os) and progression-free survival (pfs) in patients with pretreated, chemotherapy refractory, metastatic crc (mcrc). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4069DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291274PMC
December 2018
2 Reads

Reducing postsurgical exudate in breast cancer patients by using San Huang decoction to ameliorate inflammatory status: a prospective clinical trial.

Curr Oncol 2018 Dec 1;25(6):e507-e515. Epub 2018 Dec 1.

Department of Breast Disease, Affiliated Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, P.R.C.

Background: Reducing inflammatory factors in wound exudate is a promising treatment approach for healing wounds in postsurgical breast cancer patients. Traditional Chinese Medicine (tcm) treatments have been shown to be beneficial and safe for optimal regulation of oxidative stress during the postoperative period. In the present clinical trial, we evaluated the effectiveness of a promising Chinese herbal formula, San Huang decoction [shd (Radix astragali, Radix et rhizoma rhei, and Rhizoma curcuma longa, 3:1:1; supplemental Table 1)], on wound inflammatory response after mastectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291285PMC
December 2018
4 Reads

Adjuvant treatment in older patients with rectal cancer: a population-based review.

Curr Oncol 2018 Dec 1;25(6):e499-e506. Epub 2018 Dec 1.

Division of Medical Oncology, qeii Health Sciences Centre, Dalhousie University, Halifax, NS.

Background: Little is known about the benefits of adjuvant chemotherapy (adj) in the older population with locally advanced rectal cancer (larc). We evaluated use of adj, survival outcomes, and adj-related toxicity in older patients with larc.

Methods: Our retrospective review included 286 patients with larc (stages ii and iii) diagnosed between January 2010 and December 2013 in Nova Scotia who underwent curative-intent surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291269PMC
December 2018
1 Read

Patients with advanced cancer: when, why, and how to refer to palliative care services.

Curr Oncol 2018 Dec 1;25(6):403-408. Epub 2018 Dec 1.

Department of Palliative Care, Lachine Hospital Campus of the McGill University Health Centre, Lachine, QC.

Palliative care (pc) is a fundamental component of the cancer care trajectory. Its primary focus is on "the quality of life of people who have a life-threatening illness, and includes pain and symptom management, skilled psychosocial, emotional and spiritual support" to patients and loved ones. Palliative care includes, but is not limited to, end-of-life care. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4453DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291288PMC
December 2018
1 Read

The Prostate Cancer Rehabilitation Clinic: a biopsychosocial clinic for sexual dysfunction after radical prostatectomy.

Curr Oncol 2018 Dec 1;25(6):393-402. Epub 2018 Dec 1.

Department of Surgical Oncology, University Health Network, Toronto, ON.

Purpose: The most prevalent intervention for localized prostate cancer (pca) is radical prostatectomy (rp), which has a 10-year relative survival rate of more than 90%. The improved survival rate has led to a focus on reducing the burden of treatment-related morbidity and improving the patient and partner survivorship experience. Post-rp sexual dysfunction (sdf) has received significant attention, given its substantial effect on patient and partner health-related quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4111DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291273PMC
December 2018
1 Read

Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.

Curr Oncol 2018 Dec 1;25(6):384-392. Epub 2018 Dec 1.

Cross Cancer Institute, Edmonton, AB.

Background: Nivolumab was the first immuno-oncology agent available for the treatment of lung cancer in Canada. In the present study, we evaluated the real-world benefit of nivolumab in Canadian patients with lung cancer.

Methods: Patients included in the cohort were identified from a registry of patients treated through expanded access to nivolumab before and after Health Canada approval. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4287DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291291PMC
December 2018
5 Reads

Oncology communities of practice: insights from a qualitative analysis.

Curr Oncol 2018 Dec 1;25(6):378-383. Epub 2018 Dec 1.

Faculty of Medicine, University of Toronto, Toronto, ON.

Background: A community of practice (cop) is formally defined as a group of people who share a concern or a passion for something they do and who learn how to do it better as they interact regularly. Communities of practice represent a promising approach for improving cancer care outcomes. However, little research is available to guide the development of oncology cops. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291282PMC
December 2018
1 Read

Building an oncology community of practice to improve cancer care.

Curr Oncol 2018 Dec 1;25(6):371-377. Epub 2018 Dec 1.

Faculty of Medicine, University of Toronto, Toronto, ON.

Background: Communities of practice (cops) have been shown to be effective models for achieving quality outcomes in health care.

Objective: Here, we describe the application of the cop model to the Canadian oncology context.

Methods: We established an oncology cop at our urban community hospital and its networks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4087DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291277PMC
December 2018
1 Read

Outcomes by treatment modality in elderly patients with localized gastric and esophageal cancer.

Curr Oncol 2018 Dec 1;25(6):366-370. Epub 2018 Dec 1.

Princess Margaret Cancer Centre, University Health Network, Toronto, ON.

Background: We aimed to assess current treatment patterns and outcomes in elderly patients with localized gastric and esophageal (ge) cancers.

Methods: This retrospective analysis considered patients 75 years of age or older with ge cancers treated during 2012-2014. Patient demographics and tumour characteristics were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4208DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291271PMC
December 2018
1 Read

A little help from my friends: social support in palliative rehabilitation.

Curr Oncol 2018 Dec 1;25(6):358-365. Epub 2018 Dec 1.

School of Psychology, University of Ottawa, Ottawa, ON.

Background: Social support has been shown to buffer some difficulties of living with advanced cancer. The Palliative Rehabilitation Program (prp) was an interdisciplinary outpatient program offering post-treatment palliative rehabilitation to patients with advanced cancer. Social support was directly integrated into the program. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4050DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291286PMC
December 2018
2 Reads

Conflict of interest: "Be rigorous in judging ourselves and gracious in judging others".

Curr Oncol 2018 Dec 1;25(6):355-357. Epub 2018 Dec 1.

Department of Medicine, Division of Medical Oncology, The Ottawa Hospital and University of Ottawa, ON.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4587DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291281PMC
December 2018
1 Read

Medical assistance in dying for cancer patients one year after legalization: a collaborative approach at a comprehensive cancer centre.

Curr Oncol 2018 Oct 31;25(5):e486-e489. Epub 2018 Oct 31.

Department of Oncology, University of Calgary, Calgary, AB.

Medical assistance in dying (maid) is a new medical service in Canada. Access to maid for patients with advanced cancer can be daunting during periods of declining health near the end of life. In this report, we describe a collaborative approach between the centralized coordination service and a regional cancer centre as an effective strategy for enabling interdisciplinary care delivery and enhancing patient-centred care at the end of the patient's cancer journey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4118DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209548PMC
October 2018
1 Read

Opportunity is the greatest barrier to providing palliative care to advanced colorectal cancer patients: a survey of oncology clinicians.

Curr Oncol 2018 Oct 31;25(5):e480-e485. Epub 2018 Oct 31.

Department of Oncology, University of Calgary, Calgary, AB.

Palliative care (pc) is part of the recommended standard of care for patients with advanced cancer. Nevertheless, delivery of pc is inconsistent. Patients who could benefit from pc services are often referred late-or not at all. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209543PMC
October 2018
14 Reads

Are patient-reported outcomes of physical function a valid substitute for objective measurements?

Curr Oncol 2018 Oct 31;25(5):e475-e479. Epub 2018 Oct 31.

Department of Medical Oncology, Cancer Center Amsterdam, Netherlands.

Background: Physical function is important for defining treatment strategies in patients with cancer and can be estimated using patient-reported outcomes (pros). Although pros are subjective, physical activity and fitness can be tested objectively with adequate, but more labour-intensive methods that are rarely used in daily clinical practice. To determine whether pros for physical function (pro-pf) accurately predict physical function, we studied their interrelationships with objective measures of physical activity and fitness in patients with cancer who had completed cancer treatment, including adjuvant or neoadjuvant chemotherapy or autologous stem-cell transplantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4080DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209559PMC
October 2018
7 Reads

Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.

Curr Oncol 2018 Oct 31;25(5):e461-e474. Epub 2018 Oct 31.

Department of Oncology, McMaster University, and Juravinski Cancer Centre, Hamilton, ON.

Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In Canada, no unified national guideline exists for the front-line treatment of cll; provincial guidelines vary and are largely based on funding. A group of clinical experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of cll. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4092DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209557PMC
October 2018
1 Read

Radiation therapy and immunotherapy-a potential combination in cancer treatment.

Curr Oncol 2018 Oct 31;25(5):e454-e460. Epub 2018 Oct 31.

Department of Oncology, Barzilai Medical Center, Ashkelon, and Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.

Background: Radiation therapy (rt) is a longstanding treatment modality for cancer. In addition, immune checkpoint blockade has been a significant development in the field of immunotherapy, modifying key immunosuppressive pathways of cancer cells.

Methods: The aim of the present work was to review current concepts of rt and immunotherapy synergism, the abscopal effect, and the molecular effects of rt in the tumour microenvironment, its influence on immune stimulation, and potential clinical outcomes that might evolve from ongoing studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209565PMC
October 2018
6 Reads

Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts.

Curr Oncol 2018 Oct 31;25(5):e444-e453. Epub 2018 Oct 31.

Division of Urology, Department of Surgery, McMaster University, Hamilton, ON.

Background: Although surgical resection remains the standard of care for localized kidney cancers, a significant proportion of patients experience systemic recurrence after surgery and hence might benefit from effective adjuvant therapy. So far, several treatment options have been evaluated in adjuvant clinical trials, but only a few have provided promising results. Nevertheless, with the recent development of targeted therapy and immunomodulatory therapy, a series of clinical trials are in progress to evaluate the potential of those novel agents in the adjuvant setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3865DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209555PMC
October 2018
7 Reads

Geographic variation in surgical practice patterns and outcomes for resected nonmetastatic gastric cancer in Ontario.

Curr Oncol 2018 Oct 31;25(5):e436-e443. Epub 2018 Oct 31.

Department of Surgery, University of Toronto, Toronto, ON.

Background: Gastrectomy with negative resection margins and adequate lymph node dissection is the cornerstone of curative treatment for gastric cancer (gc). However, gastrectomy is a complex and invasive operation with significant morbidity and mortality. Little is known about surgical practice patterns or short- and long-term outcomes in early-stage gc in Canada. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3953DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209544PMC
October 2018
9 Reads

Changes in preoperative endoscopic and percutaneous bile drainage in patients with periampullary cancer undergoing pancreaticoduodenectomy in Ontario: effect on clinical practice of a randomized trial.

Curr Oncol 2018 Oct 31;25(5):e430-e435. Epub 2018 Oct 31.

Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON.

Background: In 2010, a multicentre randomized controlled trial reported increased postoperative complications in pancreaticoduodenectomy (pde) patients undergoing preoperative biliary decompression (pbd). We evaluated the effect of that publication on rates of pbd at the population level.

Methods: This retrospective observational cohort study identified patients undergoing pde for malignancy, 2005-2013, linking them with administrative health care databases covering medical services for a population of 13. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209556PMC
October 2018
2 Reads

Elective nodal irradiation or involved-field irradiation in definitive chemoradiotherapy for esophageal squamous cell cancer: a retrospective analysis in clinical N0 patients.

Curr Oncol 2018 Oct 31;25(5):e423-e429. Epub 2018 Oct 31.

Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, P.R.C.

Objective: We compared failure patterns and survival after elective nodal irradiation (eni) or involved-field irradiation (ifi) in patients with thoracic esophageal squamous cell carcinoma (escc), clinical stage T2-4N0M0, to determine whether ifi is feasible for such patients.

Methods: Between 2005 and 2015, 126 patients with clinical stage T2-4N0M0 thoracic escc who received definitive concurrent chemoradiotherapy in Shandong Cancer Hospital and Institute and who had complete data, were analyzed retrospectively. Of those patients, 49 received ifi, and 77 received eni. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3895DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209567PMC
October 2018
10 Reads

Computed tomography-quantified body composition predicts short-term outcomes after gastrectomy in gastric cancer.

Curr Oncol 2018 Oct 31;25(5):e411-e422. Epub 2018 Oct 31.

Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing, P.R.C.

Background: Malnutrition is a common and critical problem that influences outcome in cancer patients. Body composition reflects a patient's metabolic profile and physiologic reserves, which might be the true determinant of prognosis. In the present study, which aimed to identify valuable new prognostic indicators, we investigated the association between computed tomography-quantified body composition and short-term outcomes after gastrectomy for gastric cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209549PMC
October 2018
9 Reads

Predictors of immunotherapy-induced immune-related adverse events.

Curr Oncol 2018 Oct 31;25(5):e403-e410. Epub 2018 Oct 31.

Department of Medicine, Queen's University, Kingston, ON.

Purpose: We aimed to elucidate predictive factors for the development of immune-related adverse events (iraes) in patients receiving immunotherapies for the management of advanced solid cancers.

Methods: This retrospective study involved all patients with histologically confirmed metastatic or inoperable melanoma, non-small-cell lung cancer, or renal cell carcinoma receiving immunotherapy at the Cancer Centre of Southeastern Ontario. The type and severity of iraes, as well as potential protective and exacerbating factors, were collected from patient charts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4047DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209550PMC
October 2018
9 Reads

Patients with non-small-cell lung cancer harbouring a mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

Curr Oncol 2018 Oct 31;25(5):e398-e402. Epub 2018 Oct 31.

Chest Department, chi Créteil, Créteil, France.

Background: Mutations in are rare oncogene mutations, found in 2% of non-small-cell lung cancers (nsclcs). Little information is available about the management of patients with mutated nsclc, except for those included in clinical trials. We undertook the present study to assess the clinical characteristics, management, and outcomes of those patients in a real-life setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3945DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209546PMC
October 2018
6 Reads

Paroxysmal nocturnal hemoglobinuria testing in patients with myelodysplastic syndrome in clinical practice-frequency and indications.

Curr Oncol 2018 Oct 31;25(5):e391-e397. Epub 2018 Oct 31.

Division of Hematology, St. Paul's Hospital and the University of British Columbia, Vancouver, BC.

Background: Myelodysplastic syndrome (mds) is characterized by peripheral blood cytopenias, with most patients developing significant anemia and dependence on red blood cell (rbc) transfusion. In paroxysmal nocturnal hemoglobinuria (pnh), mutations in the gene lead to lack of cell-surface glycosylphosphatidylinositol, allowing complement-mediated lysis to occur. Paroxysmal nocturnal hemoglobinuria results in direct antiglobulin test-negative hemolysis and cytopenias, and up to 50% of patients with mds test positive for pnh cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209566PMC
October 2018
9 Reads

Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.

Curr Oncol 2018 Oct 31;25(5):e385-e390. Epub 2018 Oct 31.

Princess Margaret Cancer Centre, University Health Network, Toronto, ON.

Background: Afatinib, an irreversible epidermal growth factor receptor tyrosine kinase inhibitor (egfr tki), is approved for first-line therapy in advanced mutation-positive non-small-cell lung cancer (nsclc) and has previously demonstrated activity after failure of chemotherapy and reversible egfr tkis, with improved response and progression-free survival, compared with placebo. Outcomes in pretreated patients with advanced nsclc receiving afatinib through a Canadian special access program (sap) are reported here.

Methods: Patients with nsclc progressing after at least 1 line of chemotherapy and an egfr tki were eligible to enrol in the sap. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3914DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209553PMC
October 2018
9 Reads

Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges.

Curr Oncol 2018 Oct 31;25(5):e373-e384. Epub 2018 Oct 31.

Tom Baker Cancer Centre, Calgary, AB.

Immunotherapy has emerged as a new standard of care, showing survival benefit for solid tumours in multiple disease sites and indications. The survival improvements seen in diseases that were highly resistant to traditional therapies, with a poor prognosis, are unprecedented. Although the benefits observed in clinical trials are undeniable, not all patients derive those benefits, leading to emerging combination strategies and an ongoing quest for biomarker selection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3840DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209564PMC
October 2018
7 Reads

Exploring cancer centres for physical activity and sedentary behaviour support for breast cancer survivors.

Curr Oncol 2018 Oct 31;25(5):e365-e372. Epub 2018 Oct 31.

Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON.

Background: Up to 90% of breast cancer survivors report low levels of physical activity (pa) and spend approximately 70% of the day in sedentary behaviour. Survivors might not be receiving information about the health benefits of pa and the consequences of sedentary behaviour in the context of their cancer. The primary purpose of the present study was to evaluate cancer centres for pa and sedentary behaviour information and infrastructure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.3858DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209561PMC
October 2018
8 Reads

Access to care and outcomes for neuroendocrine tumours: does socioeconomic status matter?

Curr Oncol 2018 Oct 31;25(5):e356-e364. Epub 2018 Oct 31.

Susan Leslie Clinic for Neuroendocrine Tumours, Odette Cancer Centre at Sunnybrook Health Sciences Centre, University of Toronto, ON.

Introduction: Neuroendocrine tumours (nets) are a poorly understood malignancy lacking standardized care. Differences in socioeconomic status (ses) might worsen the effect of non-standardized care. We examined the effect of ses on net peri-diagnostic care patterns and outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.35.3930DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209547PMC
October 2018
7 Reads

Immune-related adverse events of immune checkpoint inhibitors: a brief review.

Authors:
G Myers

Curr Oncol 2018 Oct 31;25(5):342-347. Epub 2018 Oct 31.

Department of Pharmacy, Horizon Health Network-The Moncton Hospital, Moncton, NB, and Canadian Association of Pharmacy in Oncology, Vancouver, BC.

Immune checkpoint inhibitors (icis) such as inhibitors of ctla-4, PD-1, and PD-L1, given as monotherapy or combination therapy have emerged as effective treatment options for immune-sensitive solid tumours and hematologic malignancies. The benefits of icis can be offset by immune-related adverse events (iraes) that leave all organ systems vulnerable and subsequently increase the risk for morbidity and mortality. Because of fluctuating onset and prolonged duration, the toxicities associated with iraes represent a shift from the understanding of conventional anticancer toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209551PMC
October 2018
6 Reads

Discrepancies between Canadian cancer research funding and site-specific cancer burden: a spotlight on ten disease sites.

Curr Oncol 2018 Oct 31;25(5):338-341. Epub 2018 Oct 31.

Canadian Partnership Against Cancer, Toronto, ON.

Background: Cancer research is essential in evaluating the safety and effectiveness of emerging cancer treatments, which in turn can lead to ground-breaking advancements in cancer care. Given limited research funding, allocating resources in alignment with societal burden is essential. However, evidence shows that such alignment does not typically occur. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209562PMC
October 2018
3 Reads

Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus.

Curr Oncol 2018 Oct 31;25(5):329-337. Epub 2018 Oct 31.

Department of Medicine, University of British Columbia, BC Cancer, Vancouver, BC.

Management of anticoagulant therapy for the treatment of venous thromboembolism (vte) in cancer patients is complex because of an increased risk of recurrent vte and major bleeding complications in those patients relative to the general population. Subgroups of patients with cancer also show variation in their risk for recurrent vte and adverse bleeding events. Accordingly, a committee of 10 Canadian clinical experts developed the consensus risk- stratification treatment algorithm presented here to provide guidance on tailoring anticoagulant treatment choices for the acute and extended treatment of symptomatic and incidental vte, to prevent recurrent vte, and to minimize the bleeding risk in patients with cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209545PMC
October 2018
19 Reads

Canadian perspectives: update on inhibition of -positive tumours in advanced non-small-cell lung cancer.

Curr Oncol 2018 Oct 31;25(5):317-328. Epub 2018 Oct 31.

University Health Network, Princess Margaret Cancer Centre, Toronto, ON.

Background: Inhibition of the anaplastic lymphoma kinase (alk) oncogenic driver in advanced non-small-cell lung carcinoma (nsclc) improves survival. In 2015, Canadian thoracic oncology specialists published a consensus guideline about the identification and treatment of positive patients, recommending use of the alk inhibitor crizotinib in the first line. New scientific literature warrants a consensus update. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4379DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209554PMC
October 2018
15 Reads

Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario.

Curr Oncol 2018 Oct 31;25(5):307-316. Epub 2018 Oct 31.

Department of Epidemiology and Biostatistics, Western University, London, ON.

Introduction: Patients with cancer of unknown primary (cup) have pathologically confirmed metastatic tumours with unidentifiable primary tumours. Currently, very little is known about the relationship between the treatment of patients with cup and their survival outcomes. Thus, we compared oncologic treatment and survival outcomes for patients in Ontario with cup against those for a cohort of patients with metastatic cancer of known primary site. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209558PMC
October 2018
7 Reads

Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites.

Curr Oncol 2018 Oct 31;25(5):300-306. Epub 2018 Oct 31.

Juravinski Hospital and Cancer Centre, Hamilton, ON.

Background: Non-Hodgkin lymphoma (nhl) is the most common hematologic malignancy. Diffuse large B-cell lymphoma (dlbcl) and follicular lymphoma (fl) constitute 55% of new nhl cases and are initially treated with rituximab-based chemoimmunotherapy. Relative to intravenous (IV) rituximab, a subcutaneous (sc) formulation approved in 2016 has comparable pharmacokinetics, efficacy, and safety, and a greatly reduced administration time; it is also preferred by patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4231DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209563PMC
October 2018
10 Reads

Only if you view it through a different lens.

Authors:
A Abusanad

Curr Oncol 2018 Oct 31;25(5):299. Epub 2018 Oct 31.

Faculty of Medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209560PMC
October 2018
8 Reads

First case of sternum replacement with a bioceramic prosthesis after radio-induced sarcoma.

Curr Oncol 2018 08 14;25(4):e351-e353. Epub 2018 Aug 14.

i.ceram, Limoges, France.

Objectives: To date, no "gold standard" technique has been developed for sternum replacement in cases of radioinduced sarcoma, which is a rare and aggressive disease. Current techniques rely on metallic prostheses, meshes, or bone grafts-procedures that that are associated with several complications. We therefore tried a new solution that might simplify and optimize this surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092061PMC
August 2018
1 Read

What characterizes cancer family history collection tools? A critical literature review.

Curr Oncol 2018 08 14;25(4):e335-e350. Epub 2018 Aug 14.

Centre de recherche du chu de Québec, Axe Oncologie, Quebec City, QC.

Background: Many tools have been developed for the standardized collection of cancer family history (fh). However, it remains unclear which tools have the potential to help health professionals overcome traditional barriers to collecting such histories. In this review, we describe the characteristics, validation process, and performance of existing tools and appraise the extent to which those tools can support health professionals in identifying and managing at-risk individuals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6092046PMC
August 2018
3 Reads